HH&L Acquisition Co.

If you purchased HH&L Acquisition Co. securities and would like to join the action, please click "Join This Action" below.


October 17, 2022.

New York, New York—Halper Sadeh LLC, a global investor rights law firm, is investigating whether the merger of HH&L Acquisition Corp. (NYSE: HHLA) and DiaCarta, Ltd. is fair to HH&L shareholders.


DiaCarta, a precision molecular diagnostics company and developer of novel oncology and infectious disease tests, and HH&L Acquisition Co., a publicly traded special purpose acquisition company, announced that they entered into a definitive business combination agreement that is expected to provide DiaCarta with access to the approximately $414 million cash from HH&L’s IPO proceeds held in trust, assuming no redemptions by HH&L’s shareholders and prior to the payment of transaction expenses, and potential additional financing to catalyze DiaCarta’s growth.


The investigation concerns whether HH&L and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for HH&L shareholders; and (2) disclose all material information necessary for HH&L shareholders to adequately assess and value the merger consideration. On behalf of HH&L shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.


Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Scroll to Top